Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage

BMJ Global Health

Volumn 1, Issue 1, 2016, Pages

  Stone, Christopher M ^a,b,c   Kastner, Randee ^a,b   Steinmann, Peter ^a,b   Chitnis, Nakul ^a,b   Tanner, Marcel ^a,b   Tediosi, Fabrizio ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016330753     PISSN: None     EISSN: 20597908     Source Type: Journal    
DOI: 10.1136/bmjgh-2015-000021     Document Type: Article

References (43)

1. Fenner F. The eradication of smallpox. Impact Sci Society 1988;38:147–58.
2. Cairncross S, Muller R, Zagaria N. Dracunculiasis (Guinea worm disease) and the eradication initiative. Clin Microbiol Rev 2002;15:223–46.
3. Molyneux DH, Hopkins DR, Zagaria N. Disease eradication, elimination, and control: the need for accurate and consistent usage. Trends Parasitol 2004;20:347–51.
4. Caplan A. Is disease eradication ethical? Lancet 2009;373:2192–3.
5. Nájera JA, González-Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication Programme (1955–1969). PLoS Med 2011;8:e1000412.
6. Cochi S, Dowdle W, ed. Disease eradication in the 21st century: implications for global health. Cambridge, MA: MIT Press, 2011.
7. Tediosi F, Steinmann P, de Savigny D, et al. Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges. PLoS Negl Trop Dis 2013;7:e2446.
8. Dowdle WR, Cochi SL. The principles and feasibility of disease eradication. Vaccine 2011;29(Suppl 4):D70–3.
9. Sicuri E, Evans DB, Tediosi F. Can economic analysis contribute to disease elimination and eradication? A systematic review. PLoS ONE 2015;10:e0130603.
10. Barrett S, Hoel M. Optimal disease eradication. Environ Dev Econ 2007;12:627–52.
11. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet 2007;369:1363–71.
12. Durrheim DN, Wynd S, Liese B, et al. Editorial: Lymphatic filariasis endemicity—an indicator of poverty? Trop Med Int Health 2004;9:843–5.
13. WHO. Fact Sheet: lymphatic Filariasis http://www.who.int/mediacentre/factsheets/fs102/en/ 2012.
14. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–223.
15. Bailey TC, Merritt MW, Tediosi F. Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis. Am J Public Health 2015;105: 629–36.
16. Perera M, Whitehead M, Molyneux D, et al. Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis. PLoS Negl Trop Dis 2007;1:e128.
17. Gyapong M, Gyapong J, Weiss M, et al. The burden of hydrocele on men in Northern Ghana. Acta Trop 2000;77:287–94.
18. Ramaiah K, Kumar K. Effect of lymphatic filariasis on school children. Acta Trop 2000;76:197–9.
19. Ichimori K, King JD, Engels D, et al. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis 2014;8:e3328.
20. de Kraker ME, Stolk WA, van Oortmarssen GJ, et al. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine–albendazole or ivermectin–albendazole combination therapy against Wuchereria bancrofti. Trop Med Int Health 2006;11:718–28.
21. Bockarie MJ, Kelly-Hope LA, Rebollo M, et al. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philos Trans R Soc Lond B Biol Sci 2013;368:20120144.
22. Mak JW, Yen PK, Lim KC, et al. Zoonotic implications of cats and dogs in filarial transmission in Peninsular Malaysia. Trop Geogr Med 1980;32:259–64.
23. Kastner RJ, Stone CM, Steinmann P, et al. What is needed to eradicate lymphatic filariasis? A model-based assessment on the impact of scaling up mass drug administration programs. PLoS Negl Trop Dis 2015;9:e0004147.
24. Norman RA, Chan MS, Srividya A, et al. The development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect 2000;124:529–41.
25. Gambhir M, Michael E. Complex ecological dynamics and eradicibility of the vector borne macroparasitic disease, lymphatic filariasis. PLoS ONE 2008;3:e2874.
26. Schroeder SA. Incidence, prevalence, and hybrid approaches to calculating disability-adjusted life years. Popul Health Metr 2012;10:19.
27. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012;380:2129–43.
28. Briggs A, Sculpher M, Claxton K, eds. Decision modelling for health economic evaluation. Oxford University Press, 2006.
29. Chu BK, Hooper PJ, Bradley MH, et al. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Negl Trop Dis 2010;4:e708.
30. WHO. Choosing interventions that are cost effective (WHO-CHOICE). http://www.who.int/choice/costs/unit_regions/en/
31. Black W. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212–14.
32. The London Declaration on Neglected Tropical Diseases. http://www.unitingtocombatntds.org/endorsements 2010.
33. Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009;27: 903–17.
34. Santatiwongchai B, Chantarastapornchit V, Wilkinson T, et al. Methodological variation in economic evaluations conducted in low- and middle-income countries: information for reference case development. PLoS ONE 2015;10:e0123853.
35. World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993.
36. Sabot O, Cohen JM, Hsiang MS, et al. Costs and financial feasibility of malaria elimination. Lancet 2010;376:1604–15.
37. Ottesen EA, Hooper PJ, Bradley M, et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008;2:e317.
38. Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 2000;13:207–22.
39. Stone CM, Lindsay SW, Chitnis N. How effective is integrated vector management against malaria and lymphatic filariasis where the diseases are transmitted by the same vector? PLoS Negl Trop Dis 2014;8:e3393.
40. Reimer LJ, Thomsen EK, Tisch DJ, et al. Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med 2013;369:745–53.
41. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis 2014;8:e3319.
42. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016;62:334–41.
43. Michael E, Malecela MN, Zervos M, et al. Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes. PLoS ONE 2008;3: e2936.